P3-2-61 - Regorafenib team: establishing new systems for proper use, promoting a medical care team

Abstract

Objective: We have established a multidisciplinary medical team and related supporting systems for safe and straightforward introduction of the new anticancer drug Regorafenib (REG), of which the accompanying adverse reactions differ from more familiar existing anticancer drugs. We report our current practice and experience. Methods: Resources for proper use and for adverse event monitoring and materials for patient-directed descriptions were prepared through our team of doctors, pharmacists, nurses, and medical social workers. Applying these measures when treating patients, we conducted introductions of REG. Results: By conducting repeated, thorough multidisciplinary explanations to the patient whenever introducing REG treatment, patient understanding such as of self-care improved and there was no adversity attributable to insufficient explanation. The monitoring of adverse events as a team enabled early detection and prompt action. Through the use of Monitoring Sheets, even staff members with less experience could identify critical items of observation, thus also serving as a training resource. Integration of Monitoring Sheets into electronic medical records allowed for ease of jointly accessible data. Standardizing treatment and improving coordination between departments raised the quality of care and the ability to intervene early when adverse events occurred. Since introducing REG, to date we have experienced cases with lowered QOL, which was caused by increase in blood pressure (frequent) and/or by dysphonia emergence, and cases with early-stage detection of hand-foot syndrome. Conclusions: A high standard of medical care was provided to patients of REG, a comparatively new anticancer drug with potentially severe adverse reactions, by promoting a multidisciplinary medical care team with supporting systems for proper use.